NASDAQ:MSON Misonix Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Misonix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.64 +0.53 (+4.77 %) (As of 09/25/2020 07:52 PM ET) Add Compare Share Today's Range$11.14Now: $11.64▼$11.8650-Day Range$11.11MA: $13.05▼$14.4052-Week Range$6.71Now: $11.64▼$22.20Volume44,900 shsAverage Volume91,943 shsMarket Capitalization$202.23 millionP/E RatioN/ADividend YieldN/ABeta1.4 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMisonix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Misonix has a forecasted upside of 80.4% from its current price of $11.64.Amount of Analyst CoverageMisonix has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesMisonix has received 121 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMisonix has received 140 “underperform” votes. (Add your “underperform” vote.)Community SentimentMisonix has received 53.64% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Misonix and other stocks. Vote “Outperform” if you believe MSON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MSON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMisonix does not currently pay a dividend.Dividend GrowthMisonix does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Misonix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 32.81% of the stock of Misonix is held by insiders.Percentage Held by Institutions40.81% of the stock of Misonix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Misonix is -11.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Misonix is -11.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMisonix has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Laboratory apparatus & furniture Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:MSON Previous Symbol CUSIPN/A CIK880432 Webwww.misonix.com Phone631-694-9555Debt Debt-to-Equity Ratio0.27 Current Ratio3.74 Quick Ratio2.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$62.48 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$8.45 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,420,000.00 Net Margins-27.88% Return on Equity-12.44% Return on Assets-9.08%Miscellaneous Employees118 Outstanding Shares17,374,000Market Cap$202.23 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $11.64 +0.53 (+4.77 %) (As of 09/25/2020 07:52 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MSON News and Ratings via Email Sign-up to receive the latest news and ratings for MSON and its competitors with MarketBeat's FREE daily newsletter. Misonix (NASDAQ:MSON) Frequently Asked Questions How has Misonix's stock been impacted by Coronavirus (COVID-19)? Misonix's stock was trading at $10.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MSON shares have increased by 9.0% and is now trading at $11.64. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Misonix? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Misonix. When is Misonix's next earnings date? Misonix is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Misonix. How were Misonix's earnings last quarter? Misonix, Inc. (NASDAQ:MSON) announced its earnings results on Thursday, September, 3rd. The medical equipment provider reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. Misonix had a negative net margin of 27.88% and a negative return on equity of 12.44%. View Misonix's earnings history. What guidance has Misonix issued on next quarter's earnings? Misonix updated its fourth quarter 2020 Pre-Market earnings guidance on Friday, July, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.5-13.5 million, compared to the consensus revenue estimate of $8.11 million. What price target have analysts set for MSON? 3 brokerages have issued 12 month price objectives for Misonix's stock. Their forecasts range from $18.00 to $23.00. On average, they expect Misonix's share price to reach $21.00 in the next year. This suggests a possible upside of 80.4% from the stock's current price. View analysts' price targets for Misonix. Who are some of Misonix's key competitors? Some companies that are related to Misonix include Carbonite (CARB), QuinStreet (QNST), PAR Technology (PAR), Mobileiron (MOBL), Gogo (GOGO), Cango (CANG), Criteo (CRTO), Endurance International Group (EIGI), Rosetta Stone (RST), Axcelis Technologies (ACLS), Benchmark Electronics (BHE), Tucows (TCX), the Rubicon Project (MGNI), Limelight Networks (LLNW) and Eastman Kodak (KODK). View all competitors. What other stocks do shareholders of Misonix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Misonix investors own include Edap Tms (EDAP), Canopy Growth (CGC), Varian Medical Systems (VAR), Sociedad Quimica y Minera de Chile (SQM), Avadel Pharmaceuticals (AVDL), Second Sight Medical Products (EYES), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Ardelyx (ARDX) and Athenex (ATNX). Who are Misonix's key executives? Misonix's management team includes the following people: Mr. Stavros George Vizirgianakis, Pres, CEO & Director (Age 49)Mr. Joseph P. Dwyer, CFO, Treasurer & Sec. (Age 63)Mr. Robert Scott Ludecker, Sr. VP of Global Sales & Marketing (Age 52)Ms. Sharon W. Klugewicz, Chief Operating Officer (Age 51)Mr. John J. Salerno, VP of Quality and Regulatory Affairs & Chief Compliance Officer (Age 64) What is Misonix's stock symbol? Misonix trades on the NASDAQ under the ticker symbol "MSON." Who are Misonix's major shareholders? Misonix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acuitas Investments LLC (1.02%), AWM Investment Company Inc. (0.97%), Nuveen Asset Management LLC (0.36%), Horton Capital Management LLC (0.32%), Bank of New York Mellon Corp (0.25%) and Charles Schwab Investment Management Inc. (0.22%). Company insiders that own Misonix stock include Christopher H Wright, Joseph J Brennan, Joseph P Dwyer, Sharon W Klugewicz and Stavros G Vizirgianakis. View institutional ownership trends for Misonix. Which institutional investors are selling Misonix stock? MSON stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, AWM Investment Company Inc., and Bridgeway Capital Management Inc.. View insider buying and selling activity for Misonix. Which institutional investors are buying Misonix stock? MSON stock was purchased by a variety of institutional investors in the last quarter, including Acuitas Investments LLC, Horton Capital Management LLC, Nuveen Asset Management LLC, California Public Employees Retirement System, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, and SG Americas Securities LLC. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, Sharon W Klugewicz, and Stavros G Vizirgianakis. View insider buying and selling activity for Misonix. How do I buy shares of Misonix? Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Misonix's stock price today? One share of MSON stock can currently be purchased for approximately $11.64. How big of a company is Misonix? Misonix has a market capitalization of $202.23 million and generates $62.48 million in revenue each year. Misonix employs 118 workers across the globe. What is Misonix's official website? The official website for Misonix is www.misonix.com. How can I contact Misonix? Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555. This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
